Navigation Links
Stem Cell Assurance Announces Engagement of Marcum LLP as its Independent Auditors
Date:2/8/2011

BOCA RATON, Fla., Feb. 8, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (Pink Sheets: SCLZ) announced today the engagement of Marcum LLP to audit its financial statements as of December 31, 2009 and 2010 and for the years then ended.  Ranked 15th among the "Top 25 Firms" by Inside Public Accounting, Marcum offers the resources of more than 1,100 professionals, including more than 150 partners, in 23 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman, China and Hong Kong.

Mark Weinreb, Stem Cell Assurance's CEO, stated, "We are very pleased to announce the engagement of Marcum as our auditors.  The auditing of our financial statements by such a prestigious accounting firm will move us closer to becoming an established company in the stem cell arena."

About Stem Cell Assurance, Inc.Stem Cell Assurance, Inc.'s goal is to become a medical center of excellence using cell and tissue regenerative therapy protocols, primarily involving a patient's own (autologous) adult stem cells (non-embryonic), allowing patients to undergo cellular-based treatments. As more and more cellular therapies become standard of care, the Company believes its strength will be its focus on the unity of medical and scientific explanations for its future clinical procedures and outcomes and its incorporation of adult stem cell collection and storage services for future personal medical applications. The Company intends to offer processing and storage of adipose-derived adult stem cells for use in certain aesthetic cosmetic treatments. The Company also operates a wholly-owned subsidiary, Stem Cellutrition™, which offers and sells facial creams and products.

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.CONTACTSMark WeinrebCEOTel: (561) 362-4142Fax: (561) 362-4451
'/>"/>

SOURCE Stem Cell Assurance, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Stem Cell Assurance to Open New Laboratory Facility in Jupiter, Florida
2. Stem Cell Assurance Announces Appointment of Mark Weinreb, M.S. as Chief Executive Officer and Board Member
3. Joseph J. Ross, M.D., F.A.C.S. Joins Stem Cell Assurance as Vice Chairman
4. Stem Cell Assurance Unveils Physician Network Offering Regenerative Cell Cosmetic and Reconstructive Applications
5. Sepha's Blue Dye Test Alternative Brings ‘Complete Automation' To Pharma-Packaging Quality Assurance
6. Blue Dye Test Alternative Installed at Bayer China for Packaging Quality Assurance Process
7. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
8. Cytochroma appoints Steven I. Engel as Vice President of Regulatory Affairs and Quality Assurance
9. Pancreatic Cancer Action Network Announces New Initiative to Double the Survival Rate for Pancreatic Cancer Patients by 2020
10. Thermal Gradient Announces Breakthrough in Fast PCR Device Technology
11. Celtic Pharma Announces Presentation of Preclinical Data at the 69th Annual Meeting of the AAD in New Orleans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... 2017   KCNQ2 Cure Alliance  and ... today announced that they have completed the first ... implicated in KCNQ2 epileptic encephalopathy. They also report ... case involving an additional KCNQ2 genetic mutation. ... Pairnomix entered into a collaboration to further explore ...
(Date:7/18/2017)... ... July 18, 2017 , ... ... that Merck, a leading science and technology company, has implemented Genedata Biologics ... the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , The need to ...
(Date:7/17/2017)... , ... July 17, 2017 , ... ... drug delivery device testing capabilities to encompass the full series of ISO 80369 ... evaluations of fittings for medical device and drug delivery systems. With this recent ...
(Date:7/17/2017)... ... July 17, 2017 , ... Panitch Schwarze Belisario ... in the BiG (Biomedical Innovation Group) annual meeting in China. , This year’s ... antigen receptor T-cell) therapy, a rapidly developing highly personalized anti-cancer technology that involves ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/6/2017)... -- Forecasts by Product Type (EAC), Biometrics, ... (Transportation & Logistics, Government & Public Sector, Utilities / ... Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality ... looking for a definitive report on the $27.9bn Access ... ...
(Date:4/5/2017)... NEW YORK , April 5, 2017 ... security, is announcing that the server component of the ... is known for providing the end-to-end security architecture that ... customers. HYPR has already secured over 15 ... system makers including manufacturers of connected home product suites ...
Breaking Biology News(10 mins):